DNA methylation in brain development and gliomagenesis

Area of Science:

• Neuro-oncology
• Cancer epigenetics
• Genomics and epigenomics

Background:

• Tumorigenesis is traditionally viewed as driven by genomic alterations activating oncogenes and inactivating tumor suppressor genes.
• Epigenomic alterations, such as promoter methylation causing gene silencing, are increasingly recognized as critical in cancer development.
• Standard genomic screening often misses these crucial epigenomic changes.

Purpose of the Study:

• To investigate the prevalence and significance of epigenomic alterations, particularly DNA methylation, in tumorigenesis.
• To explore the role of methylation in normal brain cell function and its dysfunction in brain tumors.
• To integrate epigenomic insights with traditional genomic models for a comprehensive understanding of glioma genesis and progression.

Main Methods:

• Genome-wide methylation analysis in cancer cells.
• Comparison of methylation patterns in tumor tissues versus normal brain cells.
• Correlation of methylation status with tumor characteristics, therapeutic response, and patient survival.

Main Results:

• Aberrant methylation is highly prevalent in tumors, especially in low-grade gliomas where genomic alterations are less common.
• Methylation abnormalities significantly impact tumor progression and patient survival.
• Specific methylation patterns are linked to tumor response to therapy.

Conclusions:

• Our understanding of tumor genomes is incomplete, with many prognostic and therapeutic targets potentially residing in the epigenome.
• Aberrant DNA methylation is a key driver in glioma development and progression, necessitating its consideration alongside genomic alterations.
• Further research integrating genomic and epigenomic data is vital for advancing brain tumor diagnosis and treatment.